Feasibility of Semaglutide in Advanced Lung Disease
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
Sponsor: University of Pennsylvania
You may qualify if…
- ✓ Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
- ✓ Age \> 18
- ✓ BMI \> 30 kg/m2
- ✓ Requires supplemental oxygen on exertion
- ✓ Stable treatment regimen X 90 days
- ✓ Use of disease-modifying therapy
You may not qualify if…
- ✕ Diabetes
- ✕ Pregnant or Breastfeeding
- ✕ Recent weight loss
- ✕ Recent or chronic GI complaints
- ✕ History of gastroparesis
- ✕ History of scleroderma
- ✕ Hospitalized at time of evaluation
- ✕ Use of weight loss medication in last 90 days
Where it's recruiting
Philadelphia
Source: ClinicalTrials.gov · NCT05746039 · last updated 2026-04-21